- Home
- HFFG vs CRDF Comparison
HFFG vs CRDF Comparison
Compare HFFG & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HFFG | CRDF |
|---|---|---|
| Founded | 1997 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Food Distributors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 127.8M | 142.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | HFFG | CRDF |
|---|---|---|
| Price | $2.25 | $2.97 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $10.83 |
| AVG Volume (30 Days) | 113.1K | ★ 1.1M |
| Earning Date | 11-10-2025 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,225,541,000.00 | $501,000.00 |
| Revenue This Year | $4.36 | N/A |
| Revenue Next Year | $3.35 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 4.10 | N/A |
| 52 Week Low | $1.70 | $1.90 |
| 52 Week High | $4.93 | $4.99 |
Technical Indicators
Market Signals| Indicator | HFFG | CRDF |
|---|---|---|
| Relative Strength Index (RSI) | 43.30 | 62.77 |
| Support Level | $2.10 | $2.61 |
| Resistance Level | $2.29 | $3.31 |
| Average True Range (ATR) | 0.12 | 0.19 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 26.79 | 63.16 |
Price Performance
Historical ComparisonAbout HFFG HF Foods Group Inc.
HF Foods Group Inc is an Asian food service distributor that markets and distributes fresh produce, seafood, frozen and dry food, and non-food products to Asian restaurants and other food service customers throughout the United States. The company's business consists of one operating segment; HF Group, which operates solely in the United States. The company's customer base consists of Chinese and Asian restaurants, and it provides sales and service support to customers who mainly converse in Mandarin or Chinese dialects.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.